Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2025-12-26 @ 1:28 AM
NCT ID:
NCT03608033
Pre Assignment Details:
Patients with 24-hour UPE \> 2 g/day at baseline will be allowed to receive 12-weeks of open-label active drug (OMS721) on Week 72 (18 months post randomization), provided they meet certain criteria:
* Less than 30% reduction in UPE at the OL assessment visit from baseline UPE
* Proteinuria is ≥ 3.0 g/day at 72 weeks from randomization, confirmed by 2 measurements at least 2 weeks apart, but \< 3 weeks
* Worsening renal function, defined as a decline in eGFR of \> 5 mL/min/m\^2 from baseline
Study:
NCT03608033
Study Brief:
Results Section:
NCT03608033